The purpose of this study is to investigate advanced or metastatic solid tumors with KRAS alterations. This study evaluates the investigational medication when used alone or with other treatments.
This study evaluates the safety, tolerability, and initial effectiveness of the investigational medication. It focuses on understanding how the body processes the medication and its effects on the body.
- Who can participate: Participants aged 18 and older with advanced or metastatic solid tumors and specific KRAS alterations may join. They must have no standard treatment options or have declined such therapies.
- Study details: Participants will take the investigational medication orally, either alone or with other treatments. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last 3 years.
How understandable was the trial content above?
Hard to understand
Easy to understand